Responsibilities:
- Develop model-based strategies (translational PK/PD, mechanistic models, POPPK/PD, clinical trial simulations) to support quantitative analyses across programs; optimize dose selection, clinical trial design, and go/no-go decisions.
- Represent QP2 across cardiometabolic and ophthalmology discovery and early/late clinical development teams using quantitative approaches to streamline development.
- Collaborate with internal teams and external vendors/partners on study design, protocol development, study execution, and reporting/interpretation.
Required:
- Ph.D. (or equivalent) OR PharmD (or equivalent) with 2+ years experience OR MS (or equivalent) with 4+ years experience in pharmaceutical drug development, regulatory agency, or academia.
- Background in biopharmaceutics, pharmaceutical sciences, pharmacometrics, chemical/biomedical engineering, or related field.
- Experience with population PK and PK/PD analyses using pharmacometrics software (e.g., NONMEM, Monolix, Phoenix, etc.).
- Strong written/verbal communication, interdisciplinary collaboration, and problem scoping/planning.
Preferred:
- Knowledge of cardiometabolic and/or ophthalmology clinical drug development programs.
- Experimental design, mathematical problem solving, critical data analysis/interpretation, and statistics.
- Understanding of biopharmaceutical and ADME properties of small molecules and/or biologics.